Novo Nordisk and Gilead expand partnership

In a new phase IIb study, Novo Nordisk and Gilead plan to test a combination of three different drug treatments against nonalcoholic steatohepatitis (NASH), thereby extending the two companies' collaboration deal signed in 2019.
Photo: Novo Nordisk & Ritzau Scanpix/AP/Eric Risberg
Photo: Novo Nordisk & Ritzau Scanpix/AP/Eric Risberg
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY DANIEL FRANK CHRISTENSEN

Novo Nordisk and Gilead now declare themselves ready to expand their partnership agreement to tackle nonalcoholic steatohepatitis (NASH).

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading